Relay Therapeutics (RLAY) Profit After Tax (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Profit After Tax data on file, last reported at -$73.3 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$73.3 million, up 4.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$272.7 million (up 18.2% YoY), and the FY2025 annual result was -$276.5 million, up 18.13% from the prior year.
• Profit After Tax fell to -$73.3 million in Q1 2026 per RLAY's latest filing, from -$54.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$54.9 million in Q4 2025 and troughed at -$98.5 million in Q2 2023.
• A 5-year average of -$77.6 million and a median of -$76.8 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax surged 60.3% in 2022, then tumbled 51.89% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$67.5 million in 2022, then decreased by 23.69% to -$83.5 million in 2023, then rose by 8.97% to -$76.0 million in 2024, then rose by 27.78% to -$54.9 million in 2025, then plunged by 33.52% to -$73.3 million in 2026.
• Business Quant data shows RLAY's Profit After Tax at -$73.3 million in Q1 2026, -$54.9 million in Q4 2025, and -$74.1 million in Q3 2025.